Evaluation of Pantaprazol on cardiac and hepatic iron overload in patient with major and intermediate Thalassemia

Evaluation of Pantaprazol on cardiac and hepatic iron overload assessd by T2* MRI in patient with major and intermediate Thalassemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017042220258N40

Enrollment

Registered

2017-09-03

Start date

2017-04-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major and intermediate Thalasemia. Beta thalassaemia

Interventions

Intervention 1: Intervention group: We prescribe 1 milligram in kilogram of Pantaprazol daily before breakfast (maximum dose 40 ?milligram) for 6 months in intervention group. Intervention 2: Interven

Treatment - Drugs

Intervention group: We prescribe 1 milligram in kilogram of Pantaprazol daily before breakfast (maximum dose 40 ?milligram) for 6 months in intervention group.

Intervention group: We don't prescribe drug in control group.

Eligibility

Sex/Gender

All

Age

7 Years to 139 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with major and intermediate Thalassemia; age more than 7 years Exclusion criteria: Drug intolerance; unwilling to participate in the study; heart failure; hepatitis; HIV

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Feritin in serum. Timepoint: before and 6 months after 6 treatment. Method of measurement: Blood test.;Heart and liver iron load. Timepoint: before and 6 months after 6 treatment. Method of measurement: MRI * 2T?.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtefeh Khalilpour

Arak University of Medical Sciences

khalipour@gmail.com+98 86 3417 3638

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026